Researchers funded by The ALS Association, through donations from the ALS Ice Bucket Challenge, discovered new evidence on the role that mutant TDP-43 plays in development and progression of the disease. This important work sheds light on novel aspects of TDP-43 biology and provides valuable tools to gain insight into early stages of ALS disease progression and could lead to the development of new therapies.
Mutations in TDP-43 protein account for approximately five percent of inherited ALS cases. The mis-regulation of the mutated protein is central to disease pathways of ALS, but how these mutations cause ALS is largely unknown: both the loss of TDP-43’s function and the gain of its function has been connected to disease development and progression.
Dr. Elizabeth Fisher from the MRC Centre for Neuromuscular Disease in London and colleagues set out to better understand how TDP-43 causes ALS. They describe new TDP-43 mouse models that demonstrate significant and opposite effects on splicing events, which is validated in cells derived from people with ALS.
“This exciting new mouse model expressing physiologically relevant levels of the mutant protein with an ALS-like disease phenotype is an invaluable tool for the research community to better understand disease mechanism and explore novel therapeutic approaches,” stated Dr. Lucie Bruijn, chief scientist of The ALS Association.
What is TDP-43?
TDP-43 is a protein present in protein aggregates (clumps of protein) found in the brain and spinal cord of almost all people with ALS and other neurodegenerative diseases, such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD), among others. This accumulation of TDP-43 occurs in the cytoplasm of cells, thereby depleting TDP-43 from the nucleus where it normally resides.
Gain of Function vs. Loss of Function
How TDP-43 mutations cause ALS disease is largely unknown. Both the loss of its nuclear function, called loss of function, and its gain of function while residing in the cytoplasm in aggregates, called gain of function, have been identified as potential disease pathways.
What is splicing?
Simply stated, splicing is the editing of messenger RNA (mRNA), the instruction book to make protein. Before splicing, mRNA is made up of exons (the part of mRNA that is made into protein; also known as the coding region) and introns (the non-coding region). During splicing, the introns are removed or spliced out and the exons are joined together, readying the mRNA to be made into protein.
Here, Dr. Fisher and colleagues developed new ALS mouse models that express endogenous TDP-43 mutations, meaning the mutations are in the existing TDP-43 mouse genome. This method allows analysis of observable characteristics (phenotypes) in a more physiological setting. This contrasts with overexpressing the large amounts of TDP-43 gene copies into mice, called TDP-43 transgenic mice. TDP-43 overexpression can produce confounding effects, which hamper mice phenotype analysis.
The mutations they studied were the following:
Note that when a researcher deletes out the full TDP-43 gene, called TDP-43 null, the mice do not live beyond embryonic day six.
Why This is Important
This study identified a new disease pathway that highlights how TDP-43 gain and loss of function create their own splicing signature in an opposite manner. Importantly, this was validated in both a novel TDP-43 mouse model and in ALS patient-derived cells. This opens the possibility that the opposing gain and loss of function characteristics identified in the mice represent different stages of disease early and late stages, respectively. Together, these results represent potential therapeutic targets and furthers our understanding of ALS disease processes.
Pietro Fratta, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. The EMBO Journal. Published online May 15, 2018.
This paper is open- access.